• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis.

作者信息

Fossati Claire, Guenova Emmanuella, Conrad Curdin, Gilliet Michel, Seremet Teofila

机构信息

Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.

出版信息

J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e184-e186. doi: 10.1111/jdv.20348. Epub 2024 Sep 18.

DOI:10.1111/jdv.20348
PMID:39291931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11760681/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f9f/11760681/9feb85b004af/JDV-39-e184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f9f/11760681/9feb85b004af/JDV-39-e184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f9f/11760681/9feb85b004af/JDV-39-e184-g001.jpg

相似文献

1
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis.在使用度普利尤单抗的特应性皮炎患者和初治患者中使用曲罗芦单抗的单中心经验。
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e184-e186. doi: 10.1111/jdv.20348. Epub 2024 Sep 18.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.曲罗芦单抗治疗成人特应性皮炎患者：临床疗效、安全性、血清蛋白和总IgE水平的28周评估
Allergy. 2025 Apr;80(4):1060-1073. doi: 10.1111/all.16414. Epub 2024 Dec 14.
4
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.曲罗芦单抗与度普利尤单抗治疗中度至重度特应性皮炎第32周疗效的匹配调整间接比较
Dermatol Ther (Heidelb). 2024 Apr;14(4):983-992. doi: 10.1007/s13555-024-01143-x. Epub 2024 Apr 13.
5
Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.特应性皮炎患者出现眼部和/或面部不良事件时从度普利尤单抗转换为曲洛金单抗或 Janus 激酶抑制剂：一项多中心回顾性研究
J Allergy Clin Immunol Pract. 2025 Feb;13(2):353-360. doi: 10.1016/j.jaip.2024.12.001. Epub 2024 Dec 12.
6
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review.度普利尤单抗和曲罗芦单抗治疗肿瘤患者特应性皮炎和瘙痒性皮肤病的有效性和安全性：一项叙述性综述
Clin Cosmet Investig Dermatol. 2025 Jan 30;18:311-317. doi: 10.2147/CCID.S511559. eCollection 2025.
7
Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice.在日常实践中，使用曲罗芦单抗治疗中重度特应性皮炎患者。
Clin Exp Dermatol. 2023 Apr 27;48(5):510-517. doi: 10.1093/ced/llad038.
8
Systemic Biologic Management of Atopic Dermatitis.特应性皮炎的全身性生物治疗管理。
Adv Exp Med Biol. 2024;1447:139-149. doi: 10.1007/978-3-031-54513-9_13.
9
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis.特应性皮炎患者接受度普利尤单抗或特利鲁单抗治疗后的注射部位反应。
J Dermatolog Treat. 2024 Dec;35(1):2304027. doi: 10.1080/09546634.2024.2304027. Epub 2024 Jan 19.
10
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study.曲罗芦单抗治疗特应性皮炎患者的多数治疗目标达成：一项多中心、多国、回顾性队列研究结果。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1307-1315. doi: 10.1080/14712598.2023.2292627. Epub 2023 Dec 28.

本文引用的文献

1
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.对度普利尤单抗和JAK抑制剂无反应、不耐受或有禁忌证的患者使用曲罗芦单抗治疗取得成功：病例系列报告
J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e852-e854. doi: 10.1111/jdv.19929. Epub 2024 Feb 29.
2
Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience.特应性皮炎患者接受曲罗芦单抗治疗24周时的患者报告结局评估：一项多中心真实世界经验
J Dermatolog Treat. 2023 Dec;34(1):2285243. doi: 10.1080/09546634.2023.2285243. Epub 2023 Nov 20.
3
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors.
特利鲁单抗在真实世界中的疗效和安全性：可能的快速应答预测因素。
Dermatitis. 2024 Jan-Feb;35(S1):S77-S80. doi: 10.1089/derm.2023.0261. Epub 2023 Nov 14.
4
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results.在临床实践中用特利鲁单抗治疗重度特应性皮炎：短期疗效和安全性结果。
Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153.
5
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study.特罗利单抗治疗成人重度特应性皮炎的真实世界临床经验：一项多中心前瞻性研究。
Clin Drug Investig. 2023 Apr;43(4):299-306. doi: 10.1007/s40261-023-01258-7. Epub 2023 Apr 3.
6
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).特应性皮炎成人患者中，在对环孢素A反应不足或不耐受时，使用曲罗芦单抗联合外用皮质类固醇：一项安慰剂对照、随机、III期临床试验（ECZTRA 7）
Br J Dermatol. 2022 Mar;186(3):440-452. doi: 10.1111/bjd.20832. Epub 2021 Dec 22.
7
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.特应性皮炎：复杂疾病的治疗领域不断拓展。
Nat Rev Drug Discov. 2022 Jan;21(1):21-40. doi: 10.1038/s41573-021-00266-6. Epub 2021 Aug 20.
8
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.特利鲁单抗联合局部皮质类固醇治疗中重度特应性皮炎：来自双盲、随机、多中心、安慰剂对照 III 期 ECZTRA 3 试验的结果。
Br J Dermatol. 2021 Mar;184(3):450-463. doi: 10.1111/bjd.19573. Epub 2021 Feb 22.
9
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).特利鲁单抗治疗中重度特应性皮炎的两项 52 周、随机、双盲、多中心、安慰剂对照 III 期临床试验（ECZTRA1 和 ECZTRA2）结果。
Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.